Last edition
News about " Attention Deficit Hyperactivity Disorder (ADHD)"
Otsuka Receives US FDA Approval for First-in-Class SIMTRIYO
The US Food and Drug Administration (FDA) has approved Otsuka's SIMTRIYO, the first Norepinephrine, Dopamine, Serotonin Reuptake Inhibitor (NDSRI) for treating ADHD in adults and children aged 6 years and older weighing at least 20 kg.
Attention-Deficit Hyperactivity Disorder (ADHD) | 27/07/2026 | By News Bureau
Aurobindo Pharma USA To Acquire Lannett For USD 250 Million, Enter ADHD Treatment Space
Aurobindo Pharma USA Inc., has entered into a definitive agreement to acquire 100 percent membership interest in Lannett Company LLC from its parent company, Lannett Seller Holdco, Inc.
Attention Deficit Hyperactivity Disorder (ADHD) | 31/07/2025 | By Dineshwori | 629
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy